New drug combo aims to keep High-Risk nasopharyngeal cancer at bay

NCT ID NCT06277050

First seen May 17, 2026 · Last updated May 17, 2026

Summary

This study tests whether adding toripalimab (an immunotherapy) to standard capecitabine maintenance therapy works better than capecitabine alone for people with high-risk nasopharyngeal carcinoma. About 264 participants who have completed initial chemotherapy and radiation will be randomly assigned to one of two groups. The goal is to see if the combination can delay cancer progression or return.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital

    RECRUITING

    Nanchang, None Selected, 330029, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • First Affiliated hospital of Gannan Medical University

    RECRUITING

    Guangzhou, Jiangxi, 341000, China

    Contact

    Contact

    Contact

  • Ganzhou Cancer Hospital

    NOT_YET_RECRUITING

    Ganzhou, Jiangxi, 341000, China

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.